Loading
A phase 2 trial of eribulin and evexomostat in triple-negative breast cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer is a phase 2, randomised interventional study registered as NCT05570253 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 55 participants, started 2022-10-03 and due to reach its primary completion in 2027-10. Interventions recorded: Eribulin; SDX-7320; Placebo. Conditions listed: Breast Cancer; Metastatic Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Male or female with histologically and/or cytologically confirmed diagnosis of triple-negative metastatic breast cancer defined as estrogen and progesterone receptor staining ≤10%; and HER2-negative defined as IHC 0 to 1+ at enrolling institution (note: if IHC is equivocal, non-amplified status by". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Eribulin, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Eribulin, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Eribulin, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Eribulin, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Eribulin, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Eribulin, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.